![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High Efficacy and Favourable Safety of ABT-493 + ABT-530 Co-Administration for 12 Weeks in HCV Genotype 1-Infected Patients With Cirrhosis (SURVEYOR-I)
|
|
|
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Ed Gane1, Fred Poordad2, Armen Asatryan3, Jacob Lalezari4, Tarek Hassanein5, Humberto Aguilar6, Teresa I Ng3, Ran Liu3, Chih-Wei Lin3, Jens Kort3, Federico J Mensa3
1Auckland Clinical Studies, Auckland, New Zealand; 2Texas Liver Insti tute, San Antonio, Texas, United States; 3AbbVie Inc., North Chicago, Illinois, United States; 4Quest Clinical Research, San Francisco, California, United States; 5Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States; 6Louisiana Research Center, Shreveport, Louisiana, United States
![EASL1](../images/041816/041816-12/EASL1.gif)
![EASL2](../images/041816/041816-12/EASL2.gif)
![EASL3](../images/041816/041816-12/EASL3.gif)
![EASL4](../images/041816/041816-12/EASL4.gif)
![EASL5](../images/041816/041816-12/EASL5.gif)
![EASL6](../images/041816/041816-12/EASL6.gif)
![EASL7](../images/041816/041816-12/EASL7.gif)
![EASL8](../images/041816/041816-12/EASL8.gif)
![EASL9](../images/041816/041816-12/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|